Advertisement
Screener

GREENWICH LIFESCIENCES, INC. (GLSI) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Greenwich LifeSciences, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Greenwich LifeSciences, Inc. return tang equity for the quarter ending 2026-06-30 was -735.26%, a change of 2384.89% year-over-year.
  • Greenwich LifeSciences, Inc. return tang equity for the quarter ending 2026-03-31 was -431.01%, a change of 8429.31% year-over-year.
  • Greenwich LifeSciences, Inc. return tang equity for the quarter ending 2025-12-31 was -5619.21%, a change of -3698.91% year-over-year.
  • Greenwich LifeSciences, Inc. return tang equity for the quarter ending 2025-09-30 was -929.94%, a change of -719.19% year-over-year.
  • Greenwich LifeSciences, Inc. return tang equity for fiscal 2025 was -5508.29%, a change of -3587.98% from fiscal 2024.
  • Greenwich LifeSciences, Inc. return tang equity for fiscal 2024 was -1920.30%, a change of -1787.49% from fiscal 2023.
  • Greenwich LifeSciences, Inc. return tang equity for fiscal 2023 was -132.81%, a change of -73.55% from fiscal 2022.
  • Greenwich LifeSciences, Inc. return tang equity for fiscal 2022 was -59.26%, a change of -42.22% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-735.26%-$22.91M$3.12M
2026-03-31-431.01%-$22.71M$5.27M
2025-12-31-5619.21%-$19.8M$352,341.00
2025-09-30-929.94%-$20.31M$2.18M
2025-06-30-3120.14%-$18.83M$603,426.00
2025-03-31-8860.31%-$17.69M$199,607.00
2024-12-31-1920.30%-$17.41M$906,847.00
2024-09-30-210.75%-$10.5M$4.98M
2024-06-30-174.02%-$10.22M$5.87M
2024-03-31-180.60%-$9.24M$5.12M
2023-12-31-132.81%-$8.89M$6.7M
2023-09-30-101.01%-$8.94M$8.85M
2023-06-30-83.28%-$8.86M$10.64M
2023-03-31-68.35%-$7.98M$11.68M
2022-12-31-59.26%-$7.83M$13.21M
2022-09-30-48.02%-$7.4M$15.4M
2022-06-30-35.02%-$5.94M$16.96M
2022-03-31-30.47%-$5.94M$19.5M
2021-12-31-17.04%-$4.57M$26.82M
2021-09-30-11.81%-$3.36M$28.45M
2021-06-30-9.45%-$2.75M$29.15M
2021-03-31-7.45%-$2.22M$29.73M
2020-12-31-6.75%-$1.86M$27.61M
2020-09-30-22.59%-$1.05M$4.64M
2020-06-3076.32%-$1.13M-$1.48M
2020-03-31244.37%-$3.52M-$1.44M
2019-12-31249.98%-$3.43M-$1.37M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-5508.29%-$19.36M$351,438.00
2024-12-31-1920.30%-$17.41M$906,847.00
2023-12-31-132.81%-$8.89M$6.7M
2022-12-31-59.26%-$7.83M$13.21M
2021-12-31-17.04%-$4.57M$26.82M
2020-12-31-6.75%-$1.86M$27.61M
2019-12-31249.98%-$3.43M-$1.37M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73